ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -35.01% | 85.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -35.01% | 85.41% | |||
| Cost of Revenue | -24.07% | -67.05% | |||
| Gross Profit | -48.48% | 140.00% | |||
| SG&A Expenses | -5.43% | 3.05% | |||
| Depreciation & Amortization | -7.15% | -72.51% | |||
| Other Operating Expenses | -34.88% | -92.11% | |||
| Total Operating Expenses | -6.62% | -37.71% | |||
| Operating Income | 5.11% | 39.84% | |||
| Income Before Tax | 2.57% | 68.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.57% | 68.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.57% | 68.43% | |||
| EBIT | 5.11% | 39.84% | |||
| EBITDA | 4.94% | 41.01% | |||
| EPS Basic | 3.27% | 68.75% | |||
| Normalized Basic EPS | 2.91% | 42.09% | |||
| EPS Diluted | 2.08% | 67.27% | |||
| Normalized Diluted EPS | 2.91% | 42.09% | |||
| Average Basic Shares Outstanding | 0.49% | 1.04% | |||
| Average Diluted Shares Outstanding | 0.49% | 1.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||